The DOI matches its Crossref record.
A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts
Abstract
The efficacy of buprenorphine and methadone was compared in the outpatient detoxification of heroin addicts. Forty-five patients were randomized to receive either sublingual buprenorphine or oral methadone under double-dummy and double-blind conditions to study the pharmacology of buprenorphine in a 90-day detoxification protocol. The patients were administered either 2 mg buprenorphine or 30 mg methadone for 3 weeks followed by 4 weeks of dose reductions and 6 weeks of placebo medication. No significant between-group differences were seen on measures of treatment retention, drug use, or symptom report. During the hydromorphone challenge, methadone attenuated opioid effects to a greater extent than did buprenorphine on both physiologic (pupil constriction) and self-report measures. However, this did not result in greater abuse of illicit opioid drugs by subjects taking buprenorphine. The results of this clinical trial indicated that buprenorphine was acceptable to patients and as effective as methadone in the detoxification treatment of heroin addicts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480200058024 · Cited by 572
Self-citationBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000633 · Cited by 412
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R., Kimber, J., Breen, C., & Davoli, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub2 · Cited by 360
Comparison of buprenorphine and methadone in the treatment of opioid dependence
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1025 · Cited by 305
Buprenorphine for the management of opioid withdrawal
Gowing, L., Ali, R., & White, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002025.pub4 · Cited by 297
Goedel, W. C., Shapiro, A., Cerdá, M., Tsai, J. W., Hadland, S. E., & Marshall, B. D. L. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.3711 · Cited by 295
Madden, G. J., Bickel, W. K., & Jacobs, E. A. (1999) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.7.3.284 · Cited by 280
Self-citationBack, S. E., Payne, R. L., Wahlquist, A. H., Carter, R. E., Stroud, Z., Haynes, L., Hillhouse, M., Brady, K. T., & Ling, W. (2011) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2011.596982 · Cited by 277
Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine
Kuhlman, J. J., Lalani, S., Magluilo, J., Levine, B., Darwin, W. D., Johnson, R. E., & Cone, E. J. (1996) · Journal of Analytical Toxicology · doi:10.1093/jat/20.6.369 · Cited by 273
Self-citationAre detoxification programmes effective?
Mattick, R. P., & Hall, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90215-9 · Cited by 196
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
Gray, K. M., Sonne, S. C., McClure, E. A., Ghitza, U. E., Matthews, A. G., McRae-Clark, A. L., Carroll, K. M., Potter, J. S., Wiest, K., Mooney, L. J., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.04.020 · Cited by 157
“All missing UCTs (missed visit/dropout/lost-to-follow-up) were imputed as positive, a method that does not make the missing-at-random assumption and has been employed in substance use disorder treatment trials (Avants et al., 2000; Bickel et al., 1988; Budney et al., 2006; Johnson et al., 2007; Trivedi et al., 2017; W…”
MethodBuprenorphine tapering schedule and illicit opioid use
Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., Jenkins, J., Hasson, A., Annon, J., Saxon, A., et al. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02455.x · Cited by 112
Dunn, K. E., Sigmon, S. C., Strain, E. C., Heil, S. H., & Higgins, S. T. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.05.033 · Cited by 65
Chen, K. W., Comerford, A., Shinnick, P., & Ziedonis, D. M. (2010) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2009.0443 · Cited by 61
Ahmadi, J., Ahmadi, K., & Ohaeri, J. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2003.01218.x · Cited by 58
Buprenorphine for Opioid Detoxification: A Brief Review
Kosten, T. R. (2003) · Addictive Disorders & Their Treatment · doi:10.1097/00132576-200302040-00001 · Cited by 8
Strain, E. C., Preston, K. L., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994) · The American Journal on Addictions · doi:10.1111/j.1521-0391.1994.tb00380.x · Cited by 4
Self-citation
Metadata
- Authors
- Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1988-01
- Volume
- 43
- Issue
- 1
- Pages
- 72-78
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1966282663
- Cited by
- 260
- References
- 0
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.